1 / 44

Acute Lymphoblastic Leukemia An Overview

Acute Lymphoblastic Leukemia An Overview. Aziza Shad, MD. Case 1. History: 3yo boy presents to Emergency Department with a 5 day history of back pain and pain/difficulty walking On exam: Febrile with pallor, bruising, petechiae, mild hepatosplenomegaly Labs:

elia
Download Presentation

Acute Lymphoblastic Leukemia An Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acute Lymphoblastic LeukemiaAn Overview Aziza Shad, MD

  2. Case 1 • History: 3yo boy presents to Emergency Department with a 5 day history of back pain and pain/difficulty walking • On exam: Febrile with pallor, bruising, petechiae, mild hepatosplenomegaly • Labs: CBC: Hgb 6.0g, Hct 18.0, Plts 11k, WBC 13.6 (10p, 60l, 24 atypical lymphocytes, 6 blasts) ANC 136 CHEM: K normal, Uric acid 7.0 ↑, LDH 2200 ↑ • CXR: Reported as normal

  3. Peripheral smear Blasts with scant cytoplasm and prominent nucleoli Maslak, P. ASH Image Bank 2004;2004:101159

  4. Bone marrow aspirate and biopsy • BMA: Blasts have a high nuclear to cytoplasmic ratio and lack granules in the cytoplasm • BMBx: Bone marrow architecture is replaced by monotonous population of blasts Maslak, P. ASH Image Bank 2002;2002:100400 and 100526

  5. Maslak, P. ASH Image Bank 2004;2004:101200 Diagnosis? Acute Leukemia (most likely ALL)

  6. Making the diagnosis: Morphology and Immunophenotype

  7. Morphologic classification – French American British (FAB) subtypes L1 – 85% Small, uniform cell size Fine, homogeneous chromatin Scant cytoplasm Inconspicuous nucleoli L2 – 14% Large, heterogeneous cell size Irregular, clefted nuclei Variable amount of cytoplasm Nucleoli usually visible L3 – 1% Large, homogeneous cell size Prominent vacuolization Basophilic cytoplasm Nucleoli usually visible

  8. Leukemia is a Bone Marrow Diagnosis!

  9. Introduction • Leukemia accounts for about a third of all childhood cancers • About 80% of children with leukemia have ALL • 17% have AML • The remainder have rare forms of chronic leukemia

  10. Pediatric Acute Lymphoblastic Leukemia • Most common cancer of childhood • Affects children from 0 -20 years • Peak incidence is between 3 -6 years • Untreated, life expectancy is days to weeks • Modern risk-based therapy has brought the cure rate up to 75 -85% • for some sub-groups, the cure rate is close to 90%, for others, it is < 20%

  11. Acute Lymphoid Leukemia Incidence by Age

  12. Epidemiology of Pediatric ALL • Most common form of childhood leukemia • 2,500-3,000 children annually in U.S. (3 per 100,000) • Sibling relative risk is 2-4x • Monozygotic twin concordance 25% - highest in infancy, no increased risk after 7 years of age • mechanism in monozygotic twins is shared in utero circulation, with transfer of preleukemic from one twin to the other

  13. Pathophysiology • Most cases – cause unknown • Inherited genetic syndromes: • Downs syndrome, Bloom’s syndrome, Nijmegen breakage syndrome, ataxia telangiectasia • Environmental exposures • Ionizing radiation, benzene, prior chemotherapy • Other possible environmental influences • High birth weight, parental tobacco/alcohol, maternal diet, exposure to pesticides or solvents, prenatal vitamins (protective)

  14. Clinical Presentation • Symptoms directly related to marrow infiltration • Decreased WBC : fevers, infections • Decreased RBC :signs and symptoms of anemia • Decreased platelets: bruising, bleeding • Marrow infiltration: bone pain, limp • Extramedullary infiltration : lymphadenopathy, hepatosplenomegaly, mediastinal mass

  15. Remember… • A given case may have several symptoms or only a few • A normal CBC does not rule out leukemia! • Back pain/limp in pediatrics is a red flag and requires work-up • Before treating any child with steroids for any reason, stop and think about whether leukemia is in the differential diagnosis

  16. Differential Diagnosis • Non Malignant conditions: • Juvenile rheumatoid arthritis • Infectious Mononucleosis • ITP • Pertussis and Parapertusis • Aplastic Anemia • Other viral illnesses

  17. Differential Diagnosis • Malignancies: • Neuroblastoma • Retinoblastoma • Rhabomyosarcoma • NHL • Other small round blue cell tumors • Hyper-eosinophilia, other aplastic presentations

  18. Standard Work-up for ALL • History and Physical Exam • CBC, electrolytes, LDH, Uric acid • Peripheral smear • Chest X-Ray • Bone marrow aspirate and biopsy with special stains • Immunophenotyping ( flow cytometry) • Cytogenetics • Molecular diagnostics

  19. Immunophenotype Side-scatter CD10 CD19 CD45 CD138 CD22

  20. Molecular genetics • Favorable risk • TEL-AML1 (ETV6-RUNX1) fusion, t(12;21) • Hyperdiploidy (esp triple trisomies – chr 4, 10, 17; or double trisomies – chr 4, 10) • High risk • Philadelphia chromosome, t(9;22) • MLL rearrangement (11q23) • Hypodiploidy (<44 chromosomes) fusion signal

  21. Back to our patient… • Received hydration, PRBC and platelet transfusions, tumor lysis lab monitoring and prophylaxis (allopurinol) • Consented to start induction chemotherapy • Bone pain and fevers resolve within a few days, discharged home to follow up for ongoing outpatient chemotherapy • What is his prognosis?

  22. Cure Rates • Over the last 50 years, survival rates for childhood cancer have risen from 10% to almost 80% • Remarkable progress has been made in the past decade in the treatment and understanding of leukemia • Collaborative clinical trials implementing risk-stratified therapy have dramatically improved cure rates in ALL • Outcome in ALL has gone from a 6-month median survival to an 80% overall cure rate

  23. 100 80 60 40 20 Years of Diagnosis Number of Children 1995-97 1,299 1993-95 1,585 1989-93 3,402 % Survival 1983-89 3,711 1978-83 2,984 1975-78 1,313 1972-75 936 1970-72 499 1968-70 402 0 2 6 8 10 4 Total Number of Patients Treated: 16,131 Years after Study Entry Legend: Survival of CCG Patients with Newly-Diagnosed Acute Lymphoblastic Leukemia, 1968-1997. Bleyer A, Hather N, Personal Communication

  24. Prognostic Factors in Childhood ALL • Age • WBC count at presentation • Immunophenotype • Recurrent chromosomal abnormalities • Response to initial therapy • These prognostic factors have been used to stratify therapy following induction remission • Gene expression analysis • Pharmacogenomics

  25. Risk adapted therapy for Pediatric ALL • Standard, high or very-high risk groups • Patients with ‘high risk’ features get intensified chemotherapy • Patients with ‘very-high risk’ features are candidates for BMT • ‘Low risk’ group being studied – reduced intensity treatment

  26. Prognostic Factors in Childhood ALL • Clinical and Lab features • Leukemia cells characteristics • Response to initial therapy

  27. Prognostic Variables • Clinical and Lab Variables: • Age: • 1-9 yrs Best outcome 5 yr EFS 88% • 10-15 yrs 73% • >15 yrs 69% • < 12 mths 44% • < 6 mths poor outcome • Infants: Poor outcome • MLL gene, Increased WBC, CNS Leukemia • CD10 Negative • Poor initial response Pui et al, Lancet 2008

  28. Prognostic Variables • Clinical and Lab Variables: • WBC Count at Presentation: • Increasing WBC confer a poor outcome especially in patients with Precursor B-cell ALL • T-cell ALL patients with WBC > 100k have a higher risk of CNS relapse

  29. Prognostic Variables • Leukemic Cell Characteristics: • Immunophenotype: • Precursor B ALL: CD19, CD10 (cALLa), HLA-DR 80%- 85% of ALL 80% CD10 positive • Early pre-B (no sIg or cyIg) • Pre-B (cy Ig) • B-cell (sIg) 3% (FAB L3, CMYC gene trans) Mature B-cell phenotype no longer confers a poor prognosis

  30. Prognostic Variables • Leukemic Cell Characteristics: • Immunophenotype: • T- Cell ALL : CD2, CD7, CD5, CD3 Males, Older Age, High WBC, Mediastinal mass 12 % of ALL T-cell phenotype no longer confers a poor prognosis

  31. Prognostic Variables • Cytogenetics: • Favorable Prognosis • High Hyperdiploidy: 51 -65 chromosomes/cell or DNA index > 1.16 • Trisomies 4, 10, 17 • TEL/AML1 t(12;21) • Poor Prognosis • Hypoploidy: < 44 chromosomes • Philadelphia chromosome • T(4;11) with MLL-AF4 fusion

  32. Prognostic Variables • Response to Initial Therapy: • Day 7 and Day 14 BM responses Rapid response is favorable Current COG protocols • Peripheral blood response to steroids Day 7 (blasts< 1000/ul) GR is favorable BFM protocols

  33. EARLY RESPONSE TO THERAPY • Rapidity of response to initial chemotherapy is a significant predictor of long-term outcome

  34. Treatment • Induction of Remission (4 -6 weeks) • Consolidation ( 4 -8 weeks) • Interim Maintenance (8 weeks) • Delayed Intensification (8 weeks) • Maintenance (2 -3 years)

  35. Treatment • Induction of Remission Standard or Low Risk Dexamethasone Vincristine L Asparaginase High Risk Dexamethasone/Prednisone Vincristine L Asparaginase Anthracyclines (Daunomycin)

  36. Treatment • Induction of Remission Dexamethasone Low Risk Less CNS and BM relapses Better EFS Use in Adolescents Aseptic Necrosis Use in High Risk Infections

  37. Treatment • Consolidation: • Intensified CNS therapy • Delayed Intensification: • improves outcome • Anthracyclines, Cyclophosphamide

  38. Treatment • Maintenance Therapy: • Daily oral 6MP and weekly oral MTX • Severe hematopoietic toxicity with Thiopurine S Methyl Tranferase deficiency • CNS prophylactic therapy

  39. Treatment Maintenance Therapy: • VCR + Prednisone/ Dexamethasone Pulses • VCR/Prednisone pulses improved EFS • Dexamethasone in 1-9 yr SR patients showed fewer CNS relapses and improved EFS compared to Prednisone • Use of Dexamethasone in Adolescents: Risk of Aseptic Necrosis and bone fractures

  40. Treatment • T-cell ALL: Intensified chemotherapy protocols Pilot trials with ARA-G • Infant ALL: Intensive chemotherapy protocols • Philadelphia +ve ALL: BMT from matched related or MUD Imatinib

  41. Relapsed ALL • Timing of Relapse: Early Relapse: Survival < 10-20% [ Relapse on therapy or 6 months off ] Late Relapse: Survival 30-40% (chemotherapy) [ Relapse 12 months off therapy] T-cell ALL: Survival < 20%

  42. Treatment of Relapsed ALL • Bone Marrow Transplantation: Early Relapse High Tumor Load (>10,000 blasts/ul) • Chemotherapy

  43. Conclusions • ALL is the commonest leukemia of childhood • Minimal evaluation should include a good H&P, peripheral smear and bone marrow exam • Simple treatment protocols utilizing common agents used for ALL treatment should be used initially • Treatment modifications should be based on institutional experience and results

More Related